Lista de obras -

A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Respons

artículo científico publicado en 2017

A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer.

artículo científico publicado en 2006

A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer

artículo científico publicado en 2008

AACR Cancer Progress Report 2014

artículo científico publicado en 2014

Abstract 970: Mass spectrometry analysis of PIK3CA mutant mammary epithelial cells identifies EGFR as a paracrine effector of PI3K in basal-like breast cancer

Abstract B015: Knock-in of PIK3CA mutations in MCF10A mammary epithelial cells modifies their proteomic profile to resemble basal-like breast cancer and stimulate EGFR-dependent cell proliferation

Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer

artículo científico publicado en 2015

Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer

artículo científico publicado en 2013

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

artículo científico publicado en 2013

Aromatase is phosphorylated in situ at serine-118.

artículo científico publicado en 2008

Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling

artículo científico publicado en 2014

Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors

scientific journal article

Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells

artículo científico publicado en 2007

Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness

artículo científico publicado en 2009

Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS

artículo científico publicado en 2008

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics

artículo científico publicado en 2014

ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.

artículo científico publicado en 2009

Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics

artículo científico publicado en 2004

Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel

artículo científico publicado en 2014

ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells

artículo científico publicado en 2002

Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells

artículo científico publicado en 2008

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.

artículo científico

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

artículo científico publicado en 2006

HER2 missense mutations have distinct effects on oncogenic signaling and migration.

artículo científico publicado en 2015

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer

artículo científico publicado en 2010

Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer

artículo científico publicado en 2009

In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts.

artículo científico publicado en 2014

Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel

artículo científico publicado en 2008

Linking changes in epithelial morphogenesis to cancer mutations using computational modeling

artículo científico publicado en 2010

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer

artículo científico publicado en 2009

Modulation of NFkappaB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility

scientific journal article

Outsmarting cancer: the power of hybrid genomic/proteomic biomarkers to predict drug response

artículo científico publicado en 2014

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

artículo científico publicado en 2014

PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization

artículo científico publicado en 2002

PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

artículo científico publicado en 2024

Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors.

artículo científico publicado en 2016

Pitfalls in RECIST Data Extraction for Clinical Trials: Beyond the Basics.

artículo científico publicado en 2015

Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies

artículo científico publicado en 2005

Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: Conference Summary Statement

artículo científico publicado en 2004

Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer

scientific article published on 30 October 2020

Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer.

artículo científico publicado en 2014

RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.

artículo científico publicado en 2010

Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity

artículo científico publicado en 2006

Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab

artículo científico publicado en 2008

Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function

artículo científico publicado en 2005

Transforming growth factor-beta induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation of retinoblastoma tumor suppressor protein

artículo científico publicado en 2004

Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer

artículo científico publicado en 2003

Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors

artículo científico publicado en 2013

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.

artículo científico publicado en 2016

Lista de obras de

A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Respons

A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer.

A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer

AACR Cancer Progress Report 2014

Abstract 970: Mass spectrometry analysis of PIK3CA mutant mammary epithelial cells identifies EGFR as a paracrine effector of PI3K in basal-like breast cancer

Abstract B015: Knock-in of PIK3CA mutations in MCF10A mammary epithelial cells modifies their proteomic profile to resemble basal-like breast cancer and stimulate EGFR-dependent cell proliferation

Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer

Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

Aromatase is phosphorylated in situ at serine-118.

Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling

Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors

Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells

Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness

Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics

ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.

Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics

Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel

ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells

Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

HER2 missense mutations have distinct effects on oncogenic signaling and migration.

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer

Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer

In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts.

Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel

Linking changes in epithelial morphogenesis to cancer mutations using computational modeling

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer

Modulation of NFkappaB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility

Outsmarting cancer: the power of hybrid genomic/proteomic biomarkers to predict drug response

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization

PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors.

Pitfalls in RECIST Data Extraction for Clinical Trials: Beyond the Basics.

Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies

Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: Conference Summary Statement

Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer

Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer.

RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.

Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity

Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab

Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function

Transforming growth factor-beta induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation of retinoblastoma tumor suppressor protein

Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer

Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.